Today is #WorldAllergyDay, a time to raise awareness around allergic diseases and asthma. While allergies and #HereditaryAngioedema (#HAE) are both known for causing swelling, they are not the same. Likewise, the medicines that treat allergic reactions are not effective in treating an HAE attack. #HAE is a bradykinin-mediated disease. Our aim is to bring better oral options—like #deucrictibant, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor—to meet the needs of people with HAE for on-demand and prophylactic treatment. Learn more about our mission to help people with HAE live normal lives through pioneering science: https://lnkd.in/egs5p4dn
Info
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
- Website
-
https://pharvaris.com
Externer Link zu Pharvaris
- Branche
- Arzneimittelherstellung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Zug
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2015
- Spezialgebiete
- Medicinal Chemistry, Hereditary Angioedema, Drug Discovery, Drug Development, Biotechnology und Pharmaceuticals
Orte
-
Primär
Grafenauweg 8
Zug, 6300, CH
-
J.H. Oortweg
Leiden, South Holland 2333, NL
-
303 Wyman St
Suite 300
Waltham, MA 02451, US
Beschäftigte von Pharvaris
Updates
-
Do you want to help us pioneer science for patient choice? Join our growing team. We’re #hiring now for the following positions: #Global Head of #Quality Reporting to SaraBeth Hahn, PharmD, RPh #GCPoversight and #Compliance Lead Reporting to Vinay Edwin, MPH Senior #MedicalScience #Liaison, West Coast Reporting to Kenneth Robinson Visit https://lnkd.in/d3zgSkK to review our open positions and apply now. #drugdevelopment #HAEawareness #NowHiring
-
People with #HereditaryAgioedema (#HAE) have a personal choice of two distinct therapeutic strategies based on clinical assessment: treatment of attacks (on-demand) or prevention of attacks (prophylactic). Our goal is to develop novel, oral on-demand and prophylactic alternatives with #deucrictibant — the only oral B2 receptor antagonist currently in clinical development for the treatment of HAE to our knowledge. Visit our website to learn more about how our treatment strategy aims to improve the quality of life for people with HAE: https://lnkd.in/gzNk4GdP #ClinicalTrials #HAEtreatment
-
On May 16, we joined together with HAE International (HAEi) and Hereditary Angioedema Association - HAEA to celebrate #HAEday. An important part of the celebration is #active4HAE, a global challenge to raise awareness about #HereditaryAngioedema (#HAE) through physical activity. At Team Pharvaris, we did our part by participating in a 27-minute walk to represent the fact that people with HAE suffer 27 swelling attacks on average per year. How did you celebrate HAE day? Let us know with a comment below. #HAEawareness
-
Pharvarians presented #deucrictibant data at the European Academy of Allergy and Clinical Immunology - EAACI Congress and the Eastern Allergy Conference this past weekend. We are grateful to the #HAE community for the continued #collaboration and support of #drugdevelopment. #TBT
-
Pharvaris hat dies direkt geteilt
Allergist/Immunologist, Health Educator, Speaker, Author, Reviewer, Researcher, Advisor, Patient Advocate.
The #EAACI2024 European Academy of Allergy and Clinical Immunology - EAACI in #Valencia was an amazing experience! I have had the privilege of participating in a global HAE advisory board, recording a video, co-authoring posters and oral presentations, and sharing experiences with friends and colleagues from around the world. An incredible opportunity to meet friends again and continue exploring and learning the latest practices in #allergy & #immunology. Thank you everyone!!
-
7
-
Pharvaris recently presented data highlighting the unique #pharmacological and #clinical properties of #deucrictibant for the treatment and prevention of #HAE attacks at the European Academy of Allergy and Clinical Immunology - EAACI Congress, the Eastern Allergy Conference, and the International Drug Discovery Sciences & Technology (IDDST) Congress. Read more about the data presented here: https://lnkd.in/eNePsr_R
-
Many faces, one family. Pharvaris is a proud supporter of hae day :-) to raise #awareness of #hae #hereditaryangioedema. Today, we celebrate #HAEday along with organizations like HAE International (HAEi) and Hereditary Angioedema Association - HAEA.
-
The Pharvaris team is presenting at the 20th Annual Congress of International Drug Discovery Science and Technology (#IDDST); the 2024 Eastern Allergy Conference (#EAC); and the European Academy of Allergy and Clinical Immunology - EAACI (#EAACI) Congress 2024. Click here to find out more about our #clinical and #nonclinical presentations: https://lnkd.in/g6H2DEsf
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses - Pharvaris N.V.
ir.pharvaris.com
-
This afternoon, Pharvaris reported our first quarter 2024 financial results and provided a business update. Read the full PR here: https://lnkd.in/giW4R_Hx Berndt Modig, Pharvaris' CEO, stated, "Pharvaris is executing from a position of financial and operational strength as we enroll in RAPIDe-3, our Phase 3 on-demand study of deucrictibant, and prepare for initiation of CHAPTER-3, our Phase 3 prophylactic study of deucrictibant. We believe deucrictibant has the potential to be the preferred therapeutic option for both the treatment and prevention of HAE attacks. Pharvaris continues to further build its team and infrastructure to support two late-stage clinical trials and prepare for the commercial launch of deucrictibant for people living with HAE.”
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update - Pharvaris N.V.
ir.pharvaris.com
Ähnliche Seiten
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang300.000.000,00 $